In vitro α1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel α(1A)-adrenoceptor selective antagonists

British Journal of Pharmacology

Volumn 127, Issue 1, 1999, Pages 252-258

  Williams, T J ^a   Blue, D R ^a   Daniels, D V ^a   Davis, B ^c   Elworthy, T ^a   Gever, J R ^a   Kava, M S ^a   Morgans, D ^a   Padilla, F ^a   Tassa, S ^a   Vimont, R L ^a   Chapple, C R ^b   Chess Williams, R ^c   Eglen, R M ^a   Clarke, D E ^d   Ford, A P D W ^a  

^a Center for Biological Research   (United States)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d NONE   (United Kingdom)

Author keywords

1 adrenoceptors; Human renal artery; Inositol phosphates; Prazosin; Prostate; Radioligand binding; Rat aorta; Ro 70 0004; RS 100329; Tamsulosin

Indexed keywords

3 [3 [4 [4 FLUORO 2 (2,2,2 TRIFLUOROETHOXY)PHENYL] 1 PIPERAZINYL]PROPYL] 5 METHYL 1H PYRIMIDINE 2,4 DIONE; 5 METHYL 3 [3 [4 [2 (2,2,2 TRIFLUOROETHOXY)PHENYL] 1 PIPERAZINYL]PROPYL] 1H PYRIMIDINE 2,4 DIONE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 1 ADRENERGIC RECEPTOR; NORADRENALIN; PRAZOSIN; TAMSULOSIN; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR ALPHA(1A); ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; INOSITOL PHOSPHATE; PIPERAZINE DERIVATIVE; RO 70-0004; SULFONAMIDE; THYMINE;

ADRENERGIC RECEPTOR BLOCKING; ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTICLE; BLADDER NECK; CHO CELL; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RADIOASSAY; RECEPTOR AFFINITY; RENAL ARTERY; SECOND MESSENGER; SMOOTH MUSCLE CONTRACTION; URETHRA; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HAMSTER; HUMAN; IN VITRO STUDY; MALE; METABOLISM; MOLECULAR CLONING; RAT; SMOOTH MUSCLE; SPRAGUE DAWLEY RAT; URINARY TRACT; VASCULAR SMOOTH MUSCLE;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CHO CELLS; CLONING, MOLECULAR; CRICETINAE; HUMANS; INOSITOL PHOSPHATES; MALE; MUSCLE, SMOOTH; MUSCLE, SMOOTH, VASCULAR; NOREPINEPHRINE; PIPERAZINES; PRAZOSIN; RABBITS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; SULFONAMIDES; THYMINE; URINARY TRACT;

EID: 0032588078     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702541     Document Type: Article

References (37)

1. Arunlakshana, O. & Schild, H.O. (1959). Some quantitative uses of drug antagonists. Br. J. Pharmacol., 14, 48-58.
2. 1C-adrenoceptors: studies in the isolated perfused kidney of rat. Br. J. Pharmacol., 115, 283-294.
3. 1-AR) antagonist tamsulosin. J. Urol., 157(4), 190.
4. 1L-adrenoceptor antagonist, RS-100975. Neurourol. Urodynam., 15, 345.
5. 1-adrenoceptor antagonists prazosin, tamsulosin and Ro 70-0004. Br. J. Pharmacol., 120, 107P.
6. Brown, E., Kendall, D.A. & Nahorski, S.R. (1984). Inositol phospholipid hydrolysis in rat cerebral cortical slices. I. Receptor characterisation. J. Neurochem., 42, 1379.
7. 1D subtype. Eur. J. Pharmacol., 297, 241-248.
8. Buzelin, J.M., Hebert, M., Blondin, P. & The Prazalf Group (1993). Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. Br. J. Urol., 72, 922-927.
9. Caine, M., Perlberg, S. & Meretyk, S. (1978). A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br. J. Urol., 50, 551-554.
10. Chapple, C.R., Stott, M., Abrams, P.H., Christmas, T.J. & Milroy, E.J.G. (1992). A 12-week placebo-controlled double blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. Br. J. Urol., 70, 285-294.
11. 1) and the concentration of inhibitor which causes 50 percent inhibition of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3108.
12. 1A-adrenoceptors expressed in Chinese hamster ovary (CHO-K1) cells. Br. J. Pharmacol., 119, 360P.
13. 1-adrenoceptor subtypes present in the human prostate. Life Sci., 54, 1595-1605.
14. Flavahan, N.A. & Vanhoutte, P.M. (1986). α-Adrenoceptor Classification in Vascular Smooth Muscle. Trends Pharmacol. Sci., 7, 347-349.
15. 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol. Pharmacol., 49, 209-215.
16. 1-Adrenoceptor Classification: Sharpening Occam's Razor. Trends Pharmacol. Sci., 15, 167-170.
17. 1-adrenoceptor classification. Br. J. Pharmacol., 121, 1127-1135.
18. 1C-adrenoceptor subtype. Mol. Pharmacol., 45, 703-708.
19. Furuya, S., Kumamoto, Y., Yokoyama, E., Tsukamoto, T., Izumi, T. & Abiko, Y. (1982). Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J. Urol., 128, 836-839.
20. 1A-adrenoceptor expressed in Chinese hamster ovary cells (CHO-K1). Pharmacologist, 39, 125.
21. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br. J. Pharmacol., 113, 723-728.
22. Hedlund, H., Andersson, K.-E. & Ek, A. (1983). Effects of prazosin in patients with benign prostatic obstruction. Br. J. Urol., 130, 275-278.
23. 1-Adrenoceptors. Pharmacol. Rev., 47, 267-270.
24. 1L-Adrenoceptor mediation of smooth muscle contraction in rabbit bladder neck: a model for lower urinary tract tissues of man. Br. J. Pharmacol., 123, 1359-1366.
25. 1 adrenoceptors: binding, functional and in vivo studies. Br. J. Pharmacol., 118, 871-878.
26. Leff, P. & Dougall, I.G. (1993). Further concerns over Cheng-Prusoff analysis. Trends Pharmacol. Sci., 141, 110-112.
27. Lepor, H. (1995). Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology, 45, 406-413.
28. 1C-) adrenoceptor subtype. Br. J. Pharmacol., 115, 781-786.
29. 3H]prazosin binding. Mol. Pharmacol., 29, 321.
30. 1-adrenoceptors: subclassification and functional aspects. In α-Adrenoceptors. pp. 193-202, Tokyo: Excerpta Medica, Ltd.
31. 1-adrenergic receptor subtypes in human prostate. J. Urol., 150, 546-551.
32. Saussy, D.L., Goetz, A.S., Queen, K.L., King, H.K., Lutz, M.W. & Rimele, T.J. (1996). Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D subtype. J. Pharmacol. Exp. Ther., 278, 136-144.
33. Taniguchi, N., Ukai, Y., Tanaka, T., Yano, J., Kimura, K., Moriyama, N. & Kawabe, K. (1997). Identification of alpha 1-adrenoceptor subtypes in human prostatic urethra. Naunyn Schmiedeberg's Arch. Pharmacol., 355, 412-416.
34. Testa, R., Guarneri, L., Angelico, P., Poggesi, E., Taddei, C., Sironi, G., Colombo, D., Sulpizio, A.C., Naselsky, D.P., Hieble, J.P. & Leonardi, A. (1997). Pharmacological characterisation of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): Role of the alpha-1L adrenoceptor in tissue selectivity, Part II. J. Pharm. Exp. Ther., 281, 1284-1293.
35. 1-adrenoceptor antagonists in rat aorta. Br. J. Pharmacol., 118, 299-310.
36. 1-Adrenoceptors mediating vasoconstriction to noradrenaline and nerve stimulation in the isolated perfused mesentery of rat. Br. J. Pharmacol., 114, 531-536.
37. 1A-AR in Chinese hamster ovary (CHO-K1) cells. Br. J. Pharmacol., 119, 359P